Total raised
—
Last: Undisclosed 2015-01
Stage
Seed
Founded
2015
Headcount
6
HQ
Yokne'am Illit
Sector
Health Tech & Life Sciences
About
N2B Ltd is developing an intranasal delivery formulation of the approved drug Rasagiline for the treatment of depression associated with Parkinsons disease (PD). The company is on a quick regulatory pathway for NDA submission through the U.S. FDA 5O5(b)(2) approach. N2Bs preclinical results indicate that intranasal delivery of Rasagiline could provide both a useful alternative to oral administration in the treatment of PD and a novel therapeutic approach for the treatment of depression in PD patients. N2B was founded as an incubator company of Youdim Pharmaceuticals.
Funding history · 1 round · — total
2015-01
Undisclosed
Undisclosed
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is N2B's primary focus in drug development?
- N2B is developing an intranasal delivery formulation of the approved drug Rasagiline for the treatment of depression associated with Parkinson's disease (PD).
- When was N2B founded and what was its initial affiliation?
- N2B was founded in January 2015 as an incubator company of Youdim Pharmaceuticals.
- What is the current operational status of N2B?
- N2B is currently inactive, having ceased operations in August 2017.
- What regulatory pathway is N2B pursuing for its drug formulation?
- N2B is pursuing a quick regulatory pathway for NDA submission through the U.S. FDA 505(b)(2) approach.
- What are the potential benefits of N2B's intranasal Rasagiline delivery?
- N2B's preclinical results suggest that intranasal delivery of Rasagiline could offer an alternative to oral administration for PD treatment and a novel approach for depression in PD patients.
- Which investor participated in N2B's funding round in January 2015?
- Youdim Pharmaceuticals was an investor in N2B's undisclosed funding round in January 2015.
- What is N2B's product stage?
- N2B's product, Rasagiline, is in the clinical trial stage.
- How many employees did N2B have?
- N2B had 6 employees.
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrug DeliveryMedical DevicesMedical Treatment & Therapeutics
Technologies
Biologicals
Target customers
Healthcare & Life SciencesHealthcarePatients
Business model
B2B
Highlights
1 PatentsVerified
Tags
pharmaceuticalsmental-healthdegenerative-diseasesneurologyparkinsontreatments